Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
01 Juni 2023 - 06:08PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form
40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
Block listing Interim Review
1
June 2023 15:05 BST
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an ris.
(Note:
Italicised terms have the same meaning as given in the Listing
Rules.)
Date: 1 June 2023
|
Name of applicant:
|
ASTRAZENECA
PLC
|
|
Name
of scheme:
|
ASTRAZENECA SHARE
OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE
SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION
SCHEME
|
|
Period
of return:
|
From:
|
1
DECEMBER 2022
|
To:
|
31
MAY 2023
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
4,818,134
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted
under scheme(s) during period (see LR3.5.7G):
|
341,752
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
4,476,382
|
|
Name
of contact:
|
Hannah
Tattersall
|
|
Telephone
number of contact:
|
+44
(0)746 498 2582
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
01 June 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Aug 2023 bis Sep 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Sep 2022 bis Sep 2023
